Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
| ADC ID |
DRG0CVRIW
|
|||||
|---|---|---|---|---|---|---|
| ADC Name |
huDS6v1.01-DM4
|
|||||
| Synonyms |
huDS6v1.01 DM4
Click to Show/Hide
|
|||||
| Organization |
Sanofi SA
|
|||||
| Drug Status |
Investigative
|
|||||
| Indication |
In total 5 Indication(s)
Breast cancer [ICD11:2C60-2C65]
Investigative
Cervical cancer [ICD11:2C77]
Investigative
Colorectal cancer [ICD11:2B91]
Investigative
Ovarian cancer [ICD11:2C73]
Investigative
Pancreatic cancer [ICD11:2C10]
Investigative
|
|||||
| Drug-to-Antibody Ratio |
3-4
|
|||||
| Structure |
|
|||||
| Antibody Name |
huDS6v1.01
|
Antibody Info | ||||
| Antigen Name |
Mucin-1 (MUC1)
|
Antigen Info | ||||
| Payload Name |
Mertansine DM4
|
Payload Info | ||||
| Therapeutic Target |
Microtubule (MT)
|
Target Info | ||||
| Linker Name |
N-succinimidyl 4-(2-pyridyldithio) butanoate (SPDB)
|
Linker Info | ||||
| Conjugate Type |
Random conjugation through nucleophilic lysines.
|
|||||
| Combination Type |
Ravtansine
|
|||||
General Information of The Activity Data Related to This ADC
Discovered Using Cell Line-derived Xenograft Model
| Standard Type | Value | Units | Cell Line | Disease Model |
|---|---|---|---|---|
| Tumor Growth Inhibition value (TGI) |
≈ 100
|
%
|
HPAC cells
|
Pancreatic adenocarcinoma
|
Revealed Based on the Cell Line Data
| Standard Type | Value | Units | Cell Line | Disease Model |
|---|---|---|---|---|
| Half Maximal Inhibitory Concentration (IC50) |
< 10
|
nM
|
KB cells
|
Human papillomavirus-related endocervical adenocarcinoma
|
Full List of Activity Data of This Antibody-drug Conjugate
Discovered Using Cell Line-derived Xenograft Model
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 100.00% (Day 37) | Positive CA6 expression (CA6 +++/++) | ||
| Method Description |
The in vivo activity of huDS6v1.01-DM4 was tested onthe HPAC pancreatic model.HPAC cells were inoculated on Day 0, and immunoconjugate treatments were given on day13 (20 ug/kg). PBS control animals were euthanized once tumor vol-umes exceeded 1000 mm3.
|
||||
| In Vivo Model | HPAC CDX model | ||||
| In Vitro Model | Pancreatic adenocarcinoma | HPAC cells | CVCL_3517 | ||
Revealed Based on the Cell Line Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) | < 10.00 nM | Positive CA6 expression (CA6 +++/++) | ||
| Method Description |
In the MTT assay, cells were seeded in 96-well plates ata density of 1000-5000 cells/well. The cells were plated with serial dilutions of huDS6v1.01-DM4 immunoconjugate in 200 pl of culture media. The cells and antibody/conjugate mixtures were then incubated for 2-7 d, at which time cellviability was assessed by an MTT assay.
|
||||
| In Vitro Model | Human papillomavirus-related endocervical adenocarcinoma | KB cells | CVCL_0372 | ||
References
If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.